- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
From AAD 2025 to the Future: Advancements in Dermatology to Watch
A panelist discusses how the evolving landscape of atopic dermatitis treatment is moving toward a more personalized approach that carefully balances efficacy goals with safety considerations, incorporating new targeted therapies alongside traditional options while also expressing excitement about emerging research in dermatology including novel bispecific antibodies, microbiome-based interventions, and noninvasive diagnostic technologies that may revolutionize disease management in the coming years.
EP: 1.Tildrakizumab for Nail Psoriasis: Key Findings From AAD 2025
EP: 2.AAD 2025 Insights: Treatment Patterns in Moderate to Severe Psoriasis Patients on Biologics
EP: 3.Adherence in Psoriasis Care: Barriers, Solutions, and the Road Ahead
EP: 4.Ruxolitinib Cream and Atopic Dermatitis at AAD 2025
EP: 5.JAK Inhibitors vs Cytokine Inhibitors: AAD 2025 Findings on Infection Risks
EP: 6.From AAD 2025 to the Future: Advancements in Dermatology to Watch
- How do you envision the treatment of atopic dermatitis evolving, particularly regarding the balance between efficacy, safety, and patient management?
- Please discuss any other data in the scope of dermatology released at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) that you find noteworthy to share with colleagues.
- Outside of AAD 2025, what ongoing research efforts are you most excited for in the treatment and management of dermatologic conditions? What can we look forward to through the end of the year and beyond?
Addressing KRAS Resistance, RAS(ON) Therapies Find Limelight at AACR
May 5th 2025KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, as highlighted at the 2025 meeting of the American Association for Cancer Research (AACR).
Read More
Expanding Resources, Clinical Knowledge to Enhance AYA NHL Care: Andrew Evens, DO
May 2nd 2025To better treat adolescent and young adult (AYA) patients with various subtypes of Hodgkin and non-Hodgkin lymphomas (NHL), Andrew Evens, DO, speaks to the importance of primary care, screening access, and research.
Read More
